MyFinsight
Home
Blog
About
Contact
Proceeds from issuances
of common stock in...
$18,004K
Proceeds from issuance of
common stock under...
$1,596K
Net cash provided by
financing activities
$19,975K
Net decrease in
cash, cash...
-$175,765K
Canceled cashflow
$19,975K
Maturities of marketable
securities
$133,153K
Stock-based compensation
$9,404K
Accrued expenses and
other current...
$4,119K
Depreciation and
amortization
$2,196K
Amortization of operating
lease right-of-use...
$1,580K
Prepaid expenses and
other assets
-$1,287K
Operating lease
liabilities
$205K
Loss on disposal of
property and equipment
-$160K
Net cash provided by
(used in) investing...
-$123,826K
Net cash used in
operating activities
-$71,914K
Canceled cashflow
$133,153K
Canceled cashflow
$18,951K
Purchases of marketable
securities
$255,934K
Net loss
-$87,174K
Purchases of property and
equipment
$1,045K
Net accretion of
discount on marketable...
$1,978K
Deferred revenue
-$1,252K
Accounts payable
-$461K
Back
Back
Cash Flow
Nurix Therapeutics, Inc. (NRIX)
Nurix Therapeutics, Inc. (NRIX)
source: myfinsight.com